Share
When you hear the words Alzheimer's disease, what do you think of? The truth is, the picture most of us have of the disease is incomplete. Alzheimer's disease doesn't start when someone starts to lose their memory. It actually starts years – sometimes decades – earlier. The Rethinking Alzheimer's Disease Podcast is an engaging, narrative-style podcast miniseries for those curious or motivated to learn about Alzheimer’s disease. Perhaps you have a family member with Alzheimer’s disease, or ca ...
…
continue reading
Manage episode 518048717 series 2395115
Content provided by Audioboom and OncLive® On Air. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and OncLive® On Air or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
In today’s episode, we had the pleasure of speaking with Stephen Liu, MD, about the potential role for zidesamtinib (NVL-520) for the treatment of patients with advanced non–small cell lung cancer (NSCLC) harboring ROS1 rearrangements. Dr Liu is an associate professor of medicine at Georgetown University, as well as the director of Thoracic Oncology and head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC.
In our exclusive interview, Dr Liu discussed the current standards and challenges for treating patients with ROS1-positive disease, the unique mechanism of action of zidesamtinib, and how positive findings from the phase 1/2 ARROS-1 trial (NCT05118789) may help position this agent in the ROS1-positive NSCLC treatment paradigm.
In our exclusive interview, Dr Liu discussed the current standards and challenges for treating patients with ROS1-positive disease, the unique mechanism of action of zidesamtinib, and how positive findings from the phase 1/2 ARROS-1 trial (NCT05118789) may help position this agent in the ROS1-positive NSCLC treatment paradigm.
718 episodes
))
